Search - tctmd.com

Displaying 601 - 620 of 968

Sort: Relevancy | Date

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Opinion Fellow Talk

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

Yashasvi Chugh, MD

August 05, 2019

News Features

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Yael L. Maxwell

August 02, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Todd Neale

July 29, 2019

News Industry News

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

July 16, 2019

News Daily News

Preemptive Alcohol Septal Ablation May Help Prevent LVOT Obstruction in TMVR

Yael L. Maxwell

July 11, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Industry News

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

July 01, 2019

News Industry News

Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

June 24, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

Presentation TVT 2019

Initial Experience With the JenaValve Transfemoral TAVR System in Patients With Severe Aortic Stenosis and Risk for Coronary Occlusion

Presenter: Torsten Vahl

June 15, 2019

Presentation TVT 2019

Use of a New-Generation Transcatheter Heart Valve Facilitating Valve-in-Valve TAVR and Bioprosthetic Valve Fracture in a Patient at High Risk of Coronary Obstruction

Presenter: Mark Hensey

June 14, 2019

Presentation TVT 2019

Left Main Coronary Artery Balloon Occlusion — A Simple Maneuver to Assess the Need of BASILICA

Presenter: Albert Chan

June 14, 2019

Presentation TVT 2019

Does Orienting Sapien 3 During Crimping in TAVR Affect Final Orientation to Coronaries to Impact TAV-in-TAV and Coronary Reaccess? A Pilot Study

Presenter: Gilbert Tang

June 14, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Presentation TVT 2019

What Don’t We Know About TAVR (Coronary Access, Heart Block, Thrombosis, Durability, Repeatability)? Does it Matter?

Presenter: John Webb

June 13, 2019

Presentation TVT 2019

3 Illustrative Cases (Optimal Valve Sizing, Managing Severe AV/LVOT Calcification, and Coronary Access Issues) – A Case-Based Discussion

Presenter: Tamim Nazif

June 13, 2019

Presentation TVT 2019

3 Illustrative Cases (Optimal Valve Sizing, Reducing New Pacemakers, and Coronary Access Issues) – A Case-Based Discussion

Presenter: Stanley Chetcuti

June 13, 2019

Presentation TVT 2019

CT Assessment for Bicuspid Valve TAVR. Annular or Supra-Annular Sizing? Coronary Access? TAVR Repeatability?

Presenter: Philipp Blanke

June 13, 2019

Advertisement

FDA Expands TAVR Indication to Low-Risk Patients

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

TCTMD’s Top 10 Most Popular Stories for July 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

Preemptive Alcohol Septal Ablation May Help Prevent LVOT Obstruction in TMVR

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Initial Experience With the JenaValve Transfemoral TAVR System in Patients With Severe Aortic Stenosis and Risk for Coronary Occlusion

Use of a New-Generation Transcatheter Heart Valve Facilitating Valve-in-Valve TAVR and Bioprosthetic Valve Fracture in a Patient at High Risk of Coronary Obstruction

Left Main Coronary Artery Balloon Occlusion — A Simple Maneuver to Assess the Need of BASILICA

Does Orienting Sapien 3 During Crimping in TAVR Affect Final Orientation to Coronaries to Impact TAV-in-TAV and Coronary Reaccess? A Pilot Study

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

What Don’t We Know About TAVR (Coronary Access, Heart Block, Thrombosis, Durability, Repeatability)? Does it Matter?

3 Illustrative Cases (Optimal Valve Sizing, Managing Severe AV/LVOT Calcification, and Coronary Access Issues) – A Case-Based Discussion

3 Illustrative Cases (Optimal Valve Sizing, Reducing New Pacemakers, and Coronary Access Issues) – A Case-Based Discussion

CT Assessment for Bicuspid Valve TAVR. Annular or Supra-Annular Sizing? Coronary Access? TAVR Repeatability?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content